Connor, Clark & Lunn Investment Management (CC&L)’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $214K | Sell |
5,885
-39,016
| -87% | -$1.42M | ﹤0.01% | 1412 |
|
|
2025
Q1 | $1.63M | Buy |
44,901
+17,885
| +66% | +$648K | 0.01% | 787 |
|
|
2024
Q4 | $1.14M | Sell |
27,016
-48,249
| -64% | -$2.03M | 0.01% | 886 |
|
|
2024
Q3 | $4.18M | Sell |
75,265
-87,626
| -54% | -$4.87M | 0.02% | 485 |
|
|
2024
Q2 | $6.69M | Buy |
162,891
+7,366
| +5% | +$303K | 0.03% | 360 |
|
|
2024
Q1 | $7.26M | Buy |
155,525
+69,068
| +80% | +$3.22M | 0.03% | 358 |
|
|
2023
Q4 | $4.13M | Sell |
86,457
-95,778
| -53% | -$4.58M | 0.02% | 482 |
|
|
2023
Q3 | $6.5M | Sell |
182,235
-23,796
| -12% | -$848K | 0.03% | 338 |
|
|
2023
Q2 | $9.5M | Sell |
206,031
-1,827
| -0.9% | -$84.3K | 0.05% | 261 |
|
|
2023
Q1 | $8.34M | Sell |
207,858
-22,336
| -10% | -$896K | 0.05% | 281 |
|
|
2022
Q4 | $10.7M | Buy |
230,194
+41,773
| +22% | +$1.94M | 0.06% | 222 |
|
|
2022
Q3 | $7.8M | Buy |
188,421
+155,840
| +478% | +$6.45M | 0.05% | 246 |
|
|
2022
Q2 | $1.94M | Buy |
+32,581
| New | +$1.94M | 0.01% | 476 |
|
|
2021
Q3 | – | Sell |
-2,357
| Closed | -$225K | – | 1191 |
|
|
2021
Q2 | $225K | Sell |
2,357
-13,109
| -85% | -$1.25M | ﹤0.01% | 900 |
|
|
2021
Q1 | $1.76M | Buy |
15,466
+12,840
| +489% | +$1.46M | 0.01% | 588 |
|
|
2020
Q4 | $364K | Buy |
+2,626
| New | +$364K | ﹤0.01% | 764 |
|
|
2015
Q3 | – | Sell |
-3,800
| Closed | -$389K | – | 779 |
|
|
2015
Q2 | $389K | Sell |
3,800
-1,500
| -28% | -$154K | ﹤0.01% | 458 |
|
|
2015
Q1 | $329K | Buy |
+5,300
| New | +$329K | ﹤0.01% | 446 |
|